Surgery Alone May Offer Reasonable Overall Survival for Stage I Small Cell Lung Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Surgery Alone May Offer Reasonable Overall Survival for Stage I Small Cell Lung Cancer

AURORA, Colo -- February 17, 2010 -- Research published in February’s edition of the Journal of Thoracic Oncology investigated the utilisation of surgery and the subsequent need for radiotherapy (RT) when treating stage I small cell lung cancer (SCLC).

Traditionally, SCLC treatment regimes include chemotherapy and radiotherapy for limited stage disease; however, the study concludes that in selected patients with early stage disease a lobectomy had an excellent overall survival without additional treatment.

Researchers retrospectively evaluated the outcomes of 247 patients with stage I SCLC who underwent lobectomies; these cases were identified using the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) database.

Results showed the 3- and 5-year survival rates for the patient group who underwent lobectomies without RT were 58.1% and 50.3%, respectively. For those who supplemented their surgery with RT, 3- and 5-year overall survival was 64.9% and 57.1%.

“Based on our analysis, surgery without RT may offer a reasonable survival in a selected cohort of patients who undergo lobectomy, but this needs to be validated in a prospective setting,” said lead investigator James B. Yu, MD, Yale University, Boston, Massachusetts.

“We cannot say conclusively whether patients who endure invasive surgeries can go without additional adjuvant radiation or chemotherapy, but looking forward, the study findings create a platform for advancing the understanding of the role of surgery in therapy.”

SOURCE: International Association for the Study of Lung Cancer

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities